HZ Vaccine (IN001)
Phase 2Vaccine
HZ Vaccine (IN001) is one of 14 biologic programs targeting Herpes Zoster. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Herpes Zoster
#DrugCompanyPhaseTrials
1Famvir
NovartisApproved
Zovirax
BBp Consulting, Inc
Approved
Foscavir
CClinigen, Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Recombinant Herpes Zoster Vaccine
BBeijing Luzhu Biotechnology Co., Ltd.
Phase 3
Vimpat
UCBPreclinical
Shingrix
SShenzhen Shenxin Biotechnology Co., Ltd
Phase 1
HZ Vaccine (IN001)
SShenzhen Shenxin Biotechnology Co., Ltd
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HZ Vaccine (IN001). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details